<--- Back to Details
First PageDocument Content
Hazardous Substances and New Organisms Act / Genetically modified organism / Electronic Recording Machine /  Accounting / Cetuximab / Amen / Genetic engineering / Molecular biology / Biology / ERMA
Date: 2011-04-05 02:50:32
Hazardous Substances and New Organisms Act
Genetically modified organism
Electronic Recording Machine
Accounting
Cetuximab
Amen
Genetic engineering
Molecular biology
Biology
ERMA

Add to Reading List

Source URL: www.gefree.org.nz

Download Document from Source Website

File Size: 182,00 KB

Share Document on Facebook

Similar Documents

Clinical medicine / Cancer / Medicine / Cancer treatments / Organofluorides / Angiogenesis inhibitors / Eli Lilly and Company / Bevacizumab / FOLFIRI / FOLFOXIRI / Chemotherapy regimen / Cetuximab

References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC

DocID: 1qSc2 - View Document

Bristol-Myers Squibb / Cetuximab / Eli Lilly and Company / Cancer treatments / Chemotherapy / KRAS / Colorectal cancer / Abituzumab / Panitumumab

ICECREAM: Cetuximab antibody treatment for colorectal cancer with a G13D gene mutation The ICECREAM trial has helped researchers answer an important health question. It has provided evidence that cetuximab alone is not a

DocID: 1pJVg - View Document

Genetic engineering / DNA / Isogenic human disease models / Oncology / Zinc finger nuclease / Cetuximab / KRAS / Non-homologous end joining / Gefitinib / Epidermal growth factor receptor / Biomarker / Phosphoinositide 3-kinase

Translating Genomes | Personalizing Medicine rAAV human gene editing, isogenic human disease models, phenotypic cellbased assays for precision functional genomics and targeted drug discovery  400 peer reviewed publica

DocID: 1pH8J - View Document

Bristol-Myers Squibb / Cetuximab / Eli Lilly and Company / Epidermal growth factor receptor / WT / Panitumumab / Biomarker / KRAS / Head and neck cancer

PAN01 biomarker poster ESMO 15.pdf

DocID: 1pBTA - View Document

Panitumumab / Amgen / Chemotherapy / Docetaxel / Stomach cancer / Oncology / Cetuximab

ATTAX3: Panitumumab added to docetaxel, cisplatin, fluoropyrimidine in oesophagogastric cancer The ATTAX3 trial has helped researchers answer an important health question. It has provided evidence on the value of a new c

DocID: 1p6wp - View Document